Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ATYR PHARMA, INC.

(LIFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ATyr Pharma : to Participate in Piper Sandler Investor Lung Day

10/11/2021 | 08:01am EST

SAN DIEGO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will participate in a fireside chat as part of the Piper Sandler Virtual Investor Day: Developing Therapeutics for Lung Indications on Friday, October 15, 2021, at 9:00am ET / 6:00am PT.

The discussion will be moderated by Ted Tenthoff, Senior Research Analyst at Piper Sandler.

Following the event, a replay of the fireside chat will be available on the Investor’s section of the company’s website at www.atyrpharma.com and will be available for at least 90 days.

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.

Contact:
Ashlee Dunston
Director, Investor Relations and Corporate Communications
adunston@atyrpharma.com


Primary Logo

Source: aTyr Pharma, Inc.

2021 GlobeNewswire, Inc., source Press Releases

All news about ATYR PHARMA, INC.
11/15ATyr Pharma to Present at Upcoming Investor Conferences in November
AQ
11/12ATYR PHARMA INC Management's Discussion and Analysis of Financial Condition and Result..
AQ
11/12ATyr Pharma to Present at Upcoming Investor Conferences in November
AQ
11/11HC Wainwright Adjusts aTyr Pharma's Price Target to $11 from $18, Keeps Buy Rating
MT
11/10ATyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update - Form 8..
PU
11/10ATYR PHARMA : Q3 Earnings Snapshot
AQ
11/10ATyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update
AQ
11/10ATyr Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended ..
CI
11/09ATyr Pharma Presents Research Demonstrating Effects of Novel NRP2-Targeting Antibody, A..
AQ
11/09ATyr Pharma, Inc. Presents Research Demonstrating Effects of Novel NRP2-Targeting Antib..
CI
More news
Analyst Recommendations on ATYR PHARMA, INC.
More recommendations
Financials (USD)
Sales 2021 2,52 M - -
Net income 2021 -32,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,49x
Yield 2021 -
Capitalization 224 M 224 M -
Capi. / Sales 2021 89,0x
Capi. / Sales 2022 53,1x
Nbr of Employees 42
Free-Float 97,7%
Chart ATYR PHARMA, INC.
Duration : Period :
aTyr Pharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ATYR PHARMA, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 8,06 $
Average target price 18,50 $
Spread / Average Target 130%
EPS Revisions
Managers and Directors
Sanjay S. Shukla President, Chief Executive Officer & Director
Jill M. Broadfoot Chief Financial Officer
John K. Clarke Chairman
Leslie Nangle Vice President-Research
Paul R. Schimmel Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ATYR PHARMA, INC.107.73%224
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431